Erb-041, an estrogen receptor-β agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway

Cancer Prevention Research

Volumn 7, Issue 2, 2014, Pages 186-198

  Chaudhary, Sandeep C ^a   Singh, Tripti ^a   Talwelkar, Sarang S ^a   Srivastava, Ritesh K ^a   Arumugam, Aadithya ^a   Weng, Zhiping ^a   Elmets, Craig A ^a   Afaq, Farrukh ^a   Kopelovich, Levy ^b   Athar, Mohammad ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MICE; MICE, HAIRLESS; OXAZOLES; SKIN NEOPLASMS; ULTRAVIOLET RAYS; WNT SIGNALING PATHWAY;

EID: 84893870871     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0276     Document Type: Article

References (49)

1. Cancer facts & figures: American Cancer Society. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf 2013.
2. Skin cancer facts: skin cancer. Available from: http://www.skincancer. org/skin-cancer-information/skin-cancer-facts.
3. Bickers DR, Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 2006;126:2565-75.
4. Athar M, Elmets CA, Kopelovich L. Pharmacological activation of p53 in cancer cells. Curr Pharm Des 2011;17:631-9.
5. Tang X, Kim AL, Feith DJ, Pegg AE, Russo J, Zhang H, et al. Ornithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/-mice. J Clin Invest 2004;113:867-75.
6. So PL, Fujimoto MA, Epstein EH Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther 2008;7:1275-84.
7. Chaudhary SC, Singh T, Kapur P, Weng Z, Arumugam A, Elmets CA, et al. Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis. Toxicol Appl Pharmacol 2013;268:249-55.
8. Mikulec CD, Rundhaug JE, Simper MS, Lubet RA, Fischer SM. The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome. Cancer Prev Res 2013;6:675-85.
9. Lyseng-Williamson KA, Keating GM. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma. Am J Clin Dermatol 2013;14:61-4.
10. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010;102:1835-44.
11. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen signaling via estrogen receptor {beta}. J Biol Chem 2010;285:39575-9.
12. Leung YK, Ho SM. Estrogen receptor beta: switching to a new partner and escaping from estrogen. Sci Signal 2011;4:pe19.
13. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 1998;26:3505-12.
14. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87:905-31.
15. Warner M, Gustafsson JA. The role of estrogen receptor beta (ERbeta) in malignant diseases-a new potential target for antiproliferative drugs in prevention and treatment of cancer. BiochemBiophys ResCommun 2010;396:63-6.
16. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 2006;7:497-08.
17. Wu WF, Tan XJ, Dai YB, Krishnan V, Warner M, Gustafsson JA. Targeting estrogen receptor beta in microglia and T cells to treat experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2013;110:3543-8.
18. Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, et al. Involvement of estrogen receptor variant ER-αlpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010;24:709-21.
19. Islander U, Jochems C, Lagerquist MK, Forsblad-d'Elia H, Carlsten H. Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol 2011;335:14-29.
20. Catley MC, Birrell MA, Hardaker EL, de Alba J, Farrow S, Haj-Yahia S, et al. Estrogen receptor beta: expression profile and possible anti-inflammatory role in disease. J Pharmacol Exp Ther 2008;326: 83-8.
21. Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JA, Amado F, et al. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene 2013;32:2390-402.
22. Rudolph A, Toth C, Hoffmeister M, Roth W, Herpel E, Jansen L, et al. Expression of oestrogen receptor beta and prognosis of colorectal cancer. Br J Cancer 2012;107:831-9.
23. Heikkila A, Hagstrom J, Maenpaa H, Louhimo J, Siironen P, Heiskanen I, et al. Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome. Thyroid 2013;23:456-65.
24. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010;17:319-32.
25. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 2004;164: 2003-12.
26. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 2008;180:630-6.
27. Xiu-li W, Wen-jun C, Hui-hua D, Su-ping H, Shi-long F. ERB-041, a selective ER beta agonist, inhibits iNOS production in LPS-activated peritoneal macrophages of endometriosis via suppression of NFkappaB activation. Mol Immunol 2009;46:2413-8.
28. Bradley PP, Christensen RD, Rothstein G. Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 1982;60:618-22.
29. Kaylani SZ, Xu J, Srivastava RK, Kopelovich L, Pressey JG, Athar M. Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model. Biochem Biophys Res Commun 2013;435:557-61.
30. Kurundkar D, Srivastava RK, Chaudhary SC, Ballestas ME, Kopelovich L, Elmets CA, et al. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol 2013;266:233-44.
31. Chaudhary SC, Kurundkar D, Elmets CA, Kopelovich L, Athar M. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol 2012;88:1149-56.
32. Mak P, Chang C, Pursell B, Mercurio AM. Estrogen receptor beta sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription. Proc Natl Acad Sci U S A 2013;110:4708-13.
33. Mancuso M, Gallo D, Leonardi S, Pierdomenico M, Pasquali E, De Stefano I, et al. Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis 2009;30:340-7.
34. Mukhtar H, Elmets CA. Photocarcinogenesis: mechanisms, models and human health implications. Photochem Photobiol 1996;63:356-7.
35. Kim AL, Labasi JM, Zhu Y, Tang X, McClure K, Gabel CA, et al. Role of p38MAPKin UVB-induced inflammatory responses in the skin of SKH-1 hairless mice. J Invest Dermatol 2005;124:1318-25.
36. Sullivan NJ, Tober KL, Burns EM, Schick JS, Riggenbach JA, Mace TA, et al. UV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b +myeloid cell expansion. J Invest Dermatol 2012;132: 695-702.
37. Di Piazza M, Nowell CS, Koch U, Durham AD, Radtke F. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. Cancer Cell 2012;22:479-93.
38. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006;25:6680-4.
39. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012;246:379-400.
40. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
41. Kalluri R. EMT: when epithelial cells decide to become mesenchymallike cells. J Clin Invest 2009;119:1417-9.
42. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A 2011;108:19204-9.
43. Anastas JN,Moon RT.WNTsignalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013;13:11-26.
44. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-20.
45. Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert RH, et al. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 2007;6:2626-33.
46. Wong CE, Yu JS, Quigley DA, To MD, Jen KY, Huang PY, et al. Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev 2013;27:670-82.
47. Fuxe J, Karlsson MC. TGF-βeta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 2012;22:455-61.
48. Du Q, Geller DA. Cross-Regulation Between Wnt and NF-kappaB Signaling Pathways. For Immunopathol Dis Therap 2010;1:155-81.
49. Davidson KC, Adams AM, Goodson JM, McDonald CE, Potter JC, Berndt JD, et al. Wnt/beta-catenin signaling promotes differentiation, not self-renewal, of human embryonic stem cells and is repressed by Oct4. Proc Natl Acad Sci U S A 2012;109:4485-90.